HeimDRUG • CNSX
add
Bright Minds Biosciences Inc
Við síðustu lokun
122,19 $
Dagbil
122,07 $ - 124,38 $
Árabil
33,01 $ - 170,00 $
Markaðsvirði
1,22 ma. CAD
Meðalmagn
747,00
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
CNSX
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (CAD) | des. 2025info | Breyting á/á |
|---|---|---|
Tekjur | — | — |
Rekstrarkostnaður | 6,74 m. | 325,10% |
Nettótekjur | -7,57 m. | -15.349,58% |
Hagnaðarhlutfall | — | — |
Hagnaður á hvern hlut | -0,97 | -9.800,00% |
EBITDA | — | — |
Virkt skatthlutfall | — | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (CAD) | des. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 89,05 m. | 53,80% |
Heildareignir | 90,88 m. | 55,62% |
Heildarskuldir | 1,60 m. | 179,80% |
Eigið fé alls | 89,28 m. | — |
Útistandandi hlutabréf | 9,79 m. | — |
Eiginfjárgengi | 10,65 | — |
Arðsemi eigna | -19,23% | — |
Ávöxtun eigin fjár | -19,65% | — |
Peningaflæði
Breyting á handbæru fé
| (CAD) | des. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | -7,57 m. | -15.349,58% |
Handbært fé frá rekstri | -5,82 m. | -289,18% |
Reiðufé frá fjárfestingum | — | — |
Reiðufé frá fjármögnun | 13,39 m. | -74,27% |
Breyting á handbæru fé | 6,14 m. | -88,23% |
Frjálst peningaflæði | -4,01 m. | -339,54% |
Um
Bright Minds Biosciences is an American pharmaceutical company which is developing serotonin 5-HT₂ receptor agonists for potential medical use.
It has a particular focus on serotonin 5-HT2C receptor agonists, for instance to treat rare epilepsies and other conditions. Another area of focus for the company is serotonergic psychedelics and non-hallucinogenic psychoplastogens.
The company was co-founded by Ian McDonald and Gideon Shapiro. The lead scientist at Bright Minds Biosciences was previously Alan Kozikowski. Bright Mind Biosciences was founded in 2017 and its headquarters are in New York City, New York. Wikipedia
Stofnsett
2017
Vefsvæði
Starfsfólk
26
